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Modulation of surface T cell antigen receptor (TCR)
expression is an important mechanism for the regu-
lation of immune responses and the prevention of
T cell hyperactivation and autoimmunity. The TCR
is rapidly internalized after antigen stimulation and
then degraded in lysosomes. However, few of the
molecules involved in this process have been identi-
fied. We demonstrate that the lysosomal protein
LAPTM5 negatively regulated surface TCR expres-
sion by specifically interacting with the invariant sig-
nal-transducing CD3z chain and promoting its degra-
dation without affecting other CD3 proteins, CD33,
CD3d, or CD3g. TCR downmodulation required the
polyproline-tyrosine motifs and the ubiquitin-inter-
acting motif of LAPTM5. LAPTM5 deficiency resulted
in elevated TCR expression on both CD4+CD8+ thy-
mocytes and spleen T cells after CD3 stimulation,
as well as enhanced T cell responses in vitro and
in vivo. These results identify a lysosomal protein
important for CD3z degradation and illustrate
a unique mechanism for the control of surface TCR
expression and T cell activation.
INTRODUCTION
The T cell antigen receptor (TCR) is a multisubunit complex com-
posed of the variable antigen-binding TCR ab or gd chains non-
covalently associated with the invariant signal-transducing
CD3g3, CD3d3, and CD3zz (TCRz, CD247) chains (Kuhns et al.,
2006). TCR signaling is dynamic and regulated bymultiplemech-
anisms to ensure that appropriate signals are delivered during
T cell development and to control effector functions of mature
T cells. One important mechanism for the regulation of TCR sig-
nal strength is themodulation of its cell-surface expression (Violaand Lanzavecchia, 1996). During T cell development in the thy-
mus, surface TCR is maintained at low amounts at the CD4+8+
double-positive (DP) stage, presumably to allow for optimal
positive and negative selection, and is upregulated in CD4+
and CD8+ single-positive (SP) cells that have undergone selec-
tion (Schrum et al., 2003). In the periphery, the TCR on mature
T cells is rapidly downmodulated upon antigen stimulation.
This downregulation is a critical process for the termination of
signal transduction and the prevention of T cell hyperactivation
and autoimmunity (Naramura et al., 2002).
The TCR undergoes constitutive internalization and is then
either recycled back to the plasma membrane or sorted to lyso-
somes for degradation (Liu et al., 2000; Geisler, 2004; von Essen
et al., 2004; Valitutti et al., 1997). Modification of any of these
processes would affect steady-state TCR expression on the
cell surface (Liu et al., 2000; Geisler, 2004). Similar processes
occur after TCR triggering, but the kinetics is more rapid. In DP
thymocytes, the Src-like adaptor protein (SLAP) (Sosinowski
et al., 2000, 2001) and the RING-type E3 ubiquitin ligase Casitas
B lineage lymphoma (c-Cbl) (Naramura et al., 1998; Murphy
et al., 1998) function to promote the degradation of the internal-
ized TCR. SLAP and c-Cbl together target CD3z for ubiquitina-
tion and degradation and thereby prevent the accumulation of
fully assembled recycling TCR (Wang et al., 2001; Myers et al.,
2005, 2006). Deficiency of SLAP and/or c-Cbl results in elevated
surface TCR expression in DP thymocytes and enhanced posi-
tive selection of thymocytes expressing an MHC class II-re-
stricted TCR (Sosinowski et al., 2001; Naramura et al., 1998).
Inmature T cells, another Cbl family protein, Cbl-b, plays a critical
role in negatively regulating T cell activation (Bachmaier et al.,
2000; Chiang et al., 2000) and in the downmodulation of surface
TCR after CD3 stimulation (Naramura et al., 2002). Cbl-b,
together with c-Cbl, functions to direct the internalized TCR to
the lysosomal compartment for degradation by an as-yet-un-
known mechanism (Naramura et al., 2002). T cells lacking both
Cbl-b and c-Cbl are impaired in ligand-induced TCR down-
modulation and exhibit greatly enhanced responses to CD3
stimulation.Immunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc. 33
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in a step-wise fashion, with the association of CD3z homodimer
as the final step (Call and Wucherpfennig, 2005). Although all of
the TCR components are required for the full assembly of the
TCR complex and its transport to the plasma membrane, CD3z
can be a limiting factor that determines the surface expression
of the TCR. For example, surface TCR expression in 2B4 T cells
correlated quantitatively with CD3z protein amounts (D’Oro
et al., 2002). Very recently, it was found that deficiency of
CD3z in humans caused severe combined immunodeficiency
by preventing normal TCR assembly and surface expression
(Rieux-Laucat et al., 2006; Roberts et al., 2007). In addition to
its pivotal role in regulating the assembly of newly synthesized
TCR complexes, the fate of CD3z after TCR internalization
appears to determine the destiny of the entire TCR complex,
i.e., recycling or degradation. SLAP-deficient DP thymocytes
expressed increased amounts of CD3z, but not TCRa, TCRb
or CD33, and elevated surface TCR expression as compared
with wild-type DP thymocytes (Myers et al., 2005), indicating
that the surface TCR expression in DP thymocytes is dependent
on CD3z expression. Conversely, forced expression of SLAP and
c-Cbl in Jurkat T cells resulted in decreased surface TCR, and
the ability of various SLAP and c-Cbl mutants to downregulate
surface TCR correlated with their ability to induce CD3z degra-
dation (Myers et al., 2006). Together, these observations demon-
strate that CD3z is an important component that regulates sur-
face TCR expression and T cell function. It remains largely
unclear, however, how CD3z is targeted to the lysosomes and
whether any lysosomal proteins are involved in its degradation.
During the course of identifying genes whose expression was
downregulated upon B and T cell activation, we previously iso-
lated a mouse gene and named it Clast6 (for CD40-ligand-acti-
vated specific transcripts) (Seimiya et al., 2003). Clast6 turned
out to be identical to the hematopoietic-specific genes LAPTM5
and Laptm5, identified in human and mouse, respectively (Adra
et al., 1996; Scott et al., 1996). LAPTM5 is a lysosomal protein
that contains fivemembrane-spanning segments, three polypro-
line-tyrosine (PY) motifs (L/PPxY), which are known to bind WW
domains involved in protein-protein interactions, and a ubiquitin-
interacting motif (LxxALxxSxxE) in the C terminus (Adra et al.,
1996; Hofmann and Falquet, 2001; Pak et al., 2006). In a separate
expression-cloning approach to identify genes that are involved
in TCR signaling, we also isolated a 294 bp fragment that en-
coded the 98 N-terminal amino acids of LAPTM5. When fused
with the extracellular domain of CD8, this short peptide induced
NF-AT activation in response to CD8 crosslinking, suggesting
a role for LAPTM5 in regulating T cell activation (unpublished
data). To explore its physiological role in the immune system,
here we have generated and analyzed Laptm5-gene-targeted
mice. Our results demonstrate that LAPTM5 negatively regulates
TCR signaling by promoting CD3z degradation.
RESULTS
Generation of LAPTM5-Deficient Mice
Laptm5 is preferentially expressed in lymphoid tissues and
transiently downregulated upon T and B cell activation (Fig-
ure S1 available online). We therefore employed a conventional
approach to inactivate the Laptm5 gene. We designed a target-34 Immunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc.ing vector to replace the first exon, which contains the transla-
tional initiation codon, and 859 bp of the promoter region, with
a neo gene (Figures S2A and S2B). Homologous recombination
in Bruce4 embryonic stem cells (ESCs) was verified by long-
range genomic PCR analysis with primers flanking the 50
(s157459) and 30 (as169968) arms and neo primers (neos and
neoas) (Figures S2B and S2C). The neo insertion and the geno-
types of the gene-targeted mice were monitored by genomic
PCR (Figure S2D). Immunoblot analysis revealed LAPTM5 pro-
tein expression in wild-type but not Laptm5/ thymocytes
(Figure S2E). To further verify the lack of LAPTM5 protein expres-
sion in the Laptm5/ mice, we performed immunocytological
staining of purified spleen T cells. Punctate LAPTM5 staining
was clearly evident in the cytoplasm of wild-type but not
Laptm5/ T cells (Figure S2F). These results demonstrate the
successful inactivation of the Laptm5 gene.
Laptm5/ T Cells Exhibit Elevated Responses
to CD3 Stimulation
Fluorescence-activated cell sorting (FACS) analysis of bone
marrow, thymus, and spleen cells from more than seven pairs
of wild-type and Laptm5/mice showed no evident differences
in the B and T cell populations (Figure S3), indicating that
LAPTM5 deficiency had no effect on lymphocyte development
and maturation. We next examined lymphocyte function by ana-
lyzing the proliferative responses of purified B and T cells to var-
ious activation signals in vitro. B cells responded normally to
different doses of IgM antibodies, CD40 ligand, and lipopolysac-
charide (LPS) (Figure S4). However, splenic T cells consistently
exhibited increased proliferation, as measured by [3H] thymidine
uptake (Figure 1A), and elevated production of IL-2 and IFN-g
(Figure 1B) in response to CD3 stimulation as compared with
wild-type T cells. To examine the response of individual T cells,
we analyzed cell division by a carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE) assay and cytokine production by intra-
cellular staining. Laptm5/ T cells underwentmore cell divisions
(Figure 1C, left panel) and a larger fraction of the cells expressed
IFN-g (Figure 1C, right panel) compared with wild-type T cells
(wild-type, 11.5% ± 1.7%; Laptm5/, 18.2% ± 1.0%, p <
0.05), consistent with the increased [3H] thymidine uptake and
cytokine secretion observed at the population level. However,
the intracellular levels of IFN-g on a per-cell basis were increased
only marginally in Laptm5/ T cells (mean fluorescence inten-
sity: wild-type, 55.2 ± 4.6; Laptm5/, 68.3 ± 9.3; p > 0.2;
Figure 1C, right panels), indicating that the maximum response
of individual cells was not significantly enhanced in Laptm5/
T cells. Therefore, the increased proliferation and cytokine pro-
duction in Laptm5/ T cells are more likely due to sustained ac-
tivation rather than hyperactivation of individual cells. To investi-
gate whether the elevated proliferation was due to increased IL-2
production, we first examined CD3-mediated proliferation in the
presence of different doses of IL-2. The exogenously added IL-2
increased proliferation in both wild-type and Laptm5/ T cells,
although the enhancing effect plateaued at about 10 U/ml of
IL-2 (Figure 1D, left panel). Even at high doses of IL-2,
Laptm5/ T cells still exhibited elevated proliferation after
CD3 stimulation, indicating that the enhanced proliferation was
not an indirect effect of increased IL-2 production. In keeping
with that interpretation, Laptm5/ T cells responded to CD3
Immunity
LAPTM5-Mediated CD3z Degradationstimulation better than wild-type T cells in the presence of ex-
cess IL-2 (Figure 1D, right panel). These results demonstrate
that Laptm5/ T cells are hypersensitive to TCR signaling.
Figure 1. Enhanced T Cell Responses
In Vitro and In Vivo in Laptm5/ Mice
(A) Proliferation. Purified spleen T cells (5 3 104/
well in 96-well plates) were stimulated with plate-
bound anti-CD3 with or without anti-CD28 costi-
mulation for 1 and 2 days, and T cell proliferation
was analyzed by [3H] thymidine uptake. Mean ±
SD is shown. The response of Laptm5/ T cells
plateaued on day 2, when stimulated with both
anti-CD3 and anti-CD28. Similar results were
obtained in six independent experiments.
(B) Cytokine production. Spleen T cells were stim-
ulated as in (A) for 2 days, and amount of IL-2 (left
panel) and IFN-g (right panel) in the supernatant
was measured by ELISA. Data are presented as
mean ± SD, and similar results were obtained in
three independent experiments.
(C) Increase in cell division and numbers of cyto-
kine-producing cells after CD3 stimulation of
Laptm5/ T cells. Left panel: cell division as mea-
sured by a CFSE assay; right panel: intracellular
staining of IFN-g. Cells were stimulated with
plate-bound anti-CD3 (10 mg/ml) for 2 days. The
experiments were repeated twice with similar
results.
(D) Elevated CD3 responses of Laptm5/ T cells
are independent of IL-2. Left panel: responses to
CD3 stimulation in the presence of different con-
centrations of IL-2; right panel: responses to differ-
ent amounts of CD3 stimulation in the presence of
excess IL-2. Cells were stimulated for 1 day and
analyzed by [3H] thymidine uptake. Similar results
were obtained in three independent experiments.
(E) Recall response of in vivo-activated T cells.
Mice (seven wild-type and seven Laptm5/
mice) were immunized with KLH in CFA intrader-
mally in both hind footpads, and 1 week after the
immunization, cells of popliteal draining lymph
nodes from each mouse were stimulated with
different doses of KLH for 3 days. Left panel:
IL-2 production; right panel: cell proliferation as
measured by [3H] thymidine uptake. Data are pre-
sented as mean ± SD; *, p < 0.05 (unpaired t test).
(F) Delayed-type hypersensitivity. Mice (12 wild-
type and 12 Laptm5/mice) were sensitized sub-
cutaneously with mBSA in CFA. One week after
the sensitization, mice were challenged with the
same antigen, and the footpad swelling was mea-
sured. *, p < 0.05; **, p < 0.01 (unpaired t test).
Enhanced In Vivo T Cell Responses
in Laptm5/ Mice
As a first approach to determining the in
vivo effects of LAPTM5 deficiency, we ex-
amined T cell responsiveness in an ex
vivo assay. Mice were immunized with
keyhole limpet hemocyanin (KLH) in com-
plete Freund’s adjuvant (CFA) intrader-
mally in both hind footpads. One week af-
ter immunization, whole lymph node cells
were prepared from the draining popliteal lymph nodes and stim-
ulated with different doses of KLH. Laptm5/ cells exhibited
significantly elevated IL-2 production (Figure 1E, left panel) andImmunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc. 35
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T cells expanded more efficiently and/or responded more vigor-
ously in vivo than wild-type T cells.
We next examined delayed-type hypersensitivity (DTH), an im-
mune response mediated primarily by CD4+ T cells. Mice were
sensitized subcutaneously with methylated bovine serum albu-
min (BSA) in complete Freund’s adjuvant (CFA). Seven days after
the sensitization, mice were challenged with the same antigen in
one footpad, and the footpad swelling wasmeasured. Both wild-
type and Laptm5/mice exhibited a similar increase in footpad
swelling on day 1 after antigen challenge (Figure 1F). However,
the footpad swelling quickly subsided in wild-type mice, but
persisted in Laptm5/ mice (Figure 1F), indicating that
Laptm5/ T cells had an abnormally prolonged response to
antigen stimulation.
Reduced TCR Downmodulation in Laptm5/ T Cells
To explore the mechanism for the hyperresponsiveness to CD3-
mediated signaling, we first compared cell-surface TCR expres-
sion between wild-type and Laptm5/ spleen T cells and found
no differences (Figure 2C, 0 hr) indicating that this phenotype
was not due to increased expression of the TCR in Laptm5/
T cells. In addition, wild-type and Laptm5/ T cells exhibited
a similar Ca2+ response after CD3 stimulation (Figure 2A), sug-
gesting that early signaling events, including the activation of
PLC-g1 that is essential for Ca2+ mobilization, were not en-
hanced in the absence of LAPTM5. Consistent with the normal
Ca2+ response, CD3 stimulation of wild-type and Laptm5/ T
cells induced a similar magnitude and pattern in both the overall
protein tyrosine phosphorylation and the phosphorylation of
Figure 2. Reduced TCR Downmodulation in
Laptm5/ Spleen T Cells after CD3 Stimu-
lation
(A) Normal Ca2+ influx in response to CD3 cross-
linking in Laptm5/ T cells.
(B) Upper panel: overall tyrosine phosphorylation
induced by CD3 stimulation in wild-type (lane 1)
and Laptm5/ (lane 2) T cells. Lower panels:
phosphorylation of molecules involved in T cell
activation.
(C) TCR downmodulation after CD3 stimulation.
Spleen T cells were stimulated with plate-bound
anti-CD3 and analyzed for surface TCR expres-
sion at the indicated time points. A representative
FACS profile is shown.
(D) TCR downmodulation in wild-type and
Laptm5/ T cells stimulated with anti-CD3. Aver-
age ± SD of seven independent experiments is
shown. *, p < 0.05; **, p < 0.01 (unpaired t test).
specific molecules known to be involved
in TCR signaling, including Lck, ZAP70,
LAT, Erk, JNK, and p38 (Figure 2B).
The relatively normal early signaling
events but enhanced proliferation and
cytokine production in Laptm5/ T cells
suggested that TCR signaling may not
be appropriately terminated. One potential mechanism to turn
off TCR signaling is by receptor downmodulation. We therefore
analyzed anti-CD3-induced TCR downmodulation and re-ex-
pression. Splenocytes were stimulated with plate-bound anti-
CD3, and the TCR was examined by flow cytometry. As shown
in Figure 2C, cell-surface TCR was downregulated by CD3 stim-
ulation both in wild-type and Laptm5/ T cells. After 6 hr of stim-
ulation, however, Laptm5/ T cells expressed higher amounts
of cell-surface TCR. This increase in the TCR expression per-
sisted at 12 hr and 24 hr, and even at 48 hr, after stimulation.
The increased expression of TCR was consistently observed
in seven independent experiments (Figure 2D). These results
demonstrate that Laptm5/ T cells respond normally during the
immediate early phase of CD3 stimulation but exhibit prolonged
responses, probably as a result of reduced downmodulation
of the TCR.
Reduced Degradation of CD3z in Laptm5/ T Cells
The higher expression of surface TCR in Laptm5/ T cells rela-
tive to wild-type T cells after CD3 stimulation could be due to im-
paired TCR internalization, enhanced recycling of the internal-
ized TCR back to cell surface, or impaired TCR degradation.
To distinguish among these possibilities, we first examined
TCR internalization and found that Laptm5/ T cells internali-
zed TCR with exactly the same kinetics as wild-type T cells
(Figure 3A). In addition, Laptm5/ T cells showed no evidence
of enhanced recycling of the internalized TCR (Figure 3B). These
results suggest that the elevated TCR expression observed in
Laptm5/ T cells after CD3 stimulation could be due to impaired
degradation of the internalized TCR.
The TCR has been shown to be degraded in lysosomes, and
the lysosomal localization of LAPTM5 is consistent with36 Immunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc.
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component in TCR metabolism, we examined its degradation
in spleen T cells after stimulation with plate-bound anti-CD3.
CD3z protein levels decreased both in wild-type and Laptm5/
T cells and reached the lowest levels at 12 hr after stimulation.
However, Laptm5/ T cells expressed slightly higher amounts
of CD3z compared with wild-type T cells (Figure 3C), suggesting
that CD3z degradation was reduced. The reduction in protein
degradation appeared to be CD3z-specific because the expres-
sion of CD33, CD3d, and CD3g decreased with a similar kinetics
in wild-type and Laptm5/ T cells (Figure 3C). Similar results
were obtained in seven independent experiments (Figure 3D).
An increase in CD3z protein expression has been observed in
DP thymocytes lacking either c-Cbl or SLAP, and in both cases
there was elevated cell-surface TCR on CD4+CD8+ DP but not
CD4+ or CD8+ SP thymocytes (Sosinowski et al., 2001; Nara-
mura et al., 1998; Myers et al., 2005, 2006). We therefore first
compared cell-surface TCR expression on thymocyte subpopu-
lations between wild-type and Laptm5/ mice. We have exam-
ined seven pairs of wild-type and Laptm5/ mice, and in every
case we observed a small but consistent increase in cell-surface
TCR on Laptm5/ DP but not SP thymocytes (Figure 3E). As
was the case for c-Cbl or SLAP deficiency, Laptm5/ DP thy-
mocytes expressed increased amounts of total cellular CD3z
(Figure 3F). In contrast, there was no difference in the amount
of CD33 between wild-type and Laptm5/ DP thymocytes
(Figure 3G), indicating that LAPTM5 deficiency specifically af-
fected the protein expression of CD3z at the DP stage of thymo-
cyte differentiation. These results demonstrate that LAPTM5 is
involved in CD3z degradation both in anti-CD3-stimulated
spleen T cells and in DP thymocytes.
Figure 3. Reduced CD3z degradation in
Laptm5/ T cells
(A and B) Normal TCR internalization after CD3
stimulation in Laptm5/ T cells (A), and normal re-
cycling of the internalized TCR (B). Mean ± SD of
two independent experiments are shown.
(C) Reduced CD3z degradation in Laptm5/
T cells stimulated with plate-bound anti-CD3.
(D) Degradation of CD3z, CD33, CD3d, and CD3g.
The results of seven independent experiments are
shown. *, p < 0.05 (unpaired t test).
(E–G) Elevated expression of cell-surface TCR and
total amounts of cellular CD3z in DP thymocytes of
Laptm5/ mice. Surface expression of TCR (E),
total cellular amounts of CD3z (F) and CD33 (G)
in DP and SP thymocytes of WT and Laptm5/
mice are shown. Left panels: typical FACS pro-
files; right panels: average ± SD of the results
from seven pairs of wild-type and Laptm5/
mice. *, p < 0.0001 (unpaired t test).
LAPTM5 Downmodulates Surface
TCR by Promoting the Degradation
of CD3z
To obtain direct evidence for LAPTM5-
mediated CD3z degradation, we next
performed a series of experiments in
2B4 T cells. Previous studies have dem-
onstrated that cell-surface TCR expression in 2B4 cells is quan-
titatively dependent on the amounts of CD3z (D’Oro et al., 2002).
We transduced 2B4 cells with retrovirus expressing LAPTM5-
IRES-GFP (LAPTM5) or IRES-GFP alone (GFP) as a control
and sorted the GFP-positive population. FACS analysis revealed
reduced surface TCR expression (Figure 4A, left panel), and im-
munoblot analysis demonstrated an 50% reduction in CD3z
protein amounts (Figure 4A, right panel) in cells expressing
LAPTM5 as compared with cells expressing GFP. Notably, the
amount of the CD33 was unaffected by LAPTM5 expression
(Figure 4A, right panel), demonstrating that LAPTM5 in T cells
specifically targets the endogenous CD3z for degradation.
We further examined cytokine production by 2B4 cells ex-
pressing LAPTM5 or GFP. Remarkably, IL-2 production induced
byCD3 stimulation was strongly inhibited in 2B4 cells expressing
LAPTM5 (Figure 4B, left panel). This profound inhibition of cyto-
kine production was specific to TCR-mediated signaling be-
cause PMA plus ionomycin induced a similar amount of IL-2 in
both transductants (Figure 4B, right panel). In addition, introduc-
tion of exogenous CD3z restored both surface TCR (Figure S5A)
and T cell response to CD3 stimulation (Figure S5B) in LAPTM5-
expressing 2B4 cells, demonstrating that LAPTM5 downmodu-
lates surface TCR and inhibits TCR signaling by targeting CD3z
for degradation.
To ensure that the results obtained in 2B4 T cells were not
a cell-line artifact, we further analyzed LAPTM5-mediated TCR
downmodulation in normal spleen T cells (Figure 4C). We first
stimulated T cells for 24 hr with plate-bound anti-CD3 plus
anti-CD28. This treatment induced rapid cell division and al-
lowed us to simultaneously transduce two different retroviruses
expressing either LAPTM5-IRES-hCD8 or CD3z-IRES-GFP.Immunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc. 37
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presence of plate-bound anti-CD3 for 24 or 48 hr and then
analyzed for cell-surface TCR expression on the gated pop-
ulation. Cells that were not transduced with either virus
(LAPTM5CD3z, 88.7%) expressed reduced amounts of sur-
face TCR (orange line, middle panel) as compared to uncultured
resting T cells (dotted line), which represented normal TCR
downmodulation induced by CD3 stimulation. Cells transduced
with LAPTM5 alone (LAPTM5+CD3z, 3.7%) further downmodu-
lated their surface TCR (blue line, middle panel) when compared
to nontransduced cells (orange line). This further downmodula-
tion, however, was completely restored by coexpression of
CD3z (LAPTM5+CD3z+, green line). Similar results were obtained
in two additional independent experiments, and the average
TCR expression (± standard deviation [SD]) is shown in
Figure 4C (right panel). These results provide compelling evi-
dence that LAPTM5 downmodulates surface TCR by targeting
CD3z for degradation both in a T cell hybridoma and in normal
spleen T cells.
TCR Downmodulation Requires the PY Motifs
and the UIM of LAPTM5
To determine which domains of LAPTM5 are needed to down-
modulate surface TCR, we generated a series of LAPTM5-
IRES-GFP constructs (Figure S6A) and transduced into 2B4
cells. Surface TCR expression was analyzed on GFP+ versus
GFP cells by flow cytometry (Figure S6B). Whereas mutation
of the first PYmotif (mPY1) did not affect the function of LAPTM5,
mutation of the third PY motif (mPY3) eliminated the ability of
LAPTM5 to downmodulate TCR (Figure 5A). Mutation of the sec-
ond PY motif (mPY2) also abolished the ability to downmodulate
TCR. However, because mPY2 was poorly expressed in 2B4
cells (Figure 5B), it is unclear whether the lack of TCR downmo-
dulation was solely attributable to the lack of PY2motif. It should
be noted that the mPY2mutant as well as other constructs could
be efficiently expressed in 293T cells (not shown). Mutation of
the ubiquitin-interacting motif (mUIM) also decreased the ability
of LAPTM5 to downmodulate TCR (Figure 5A). Unexpectedly,
when the three PY motifs were all mutated (mPY1-3) and
expressed in 2B4, not only was surface TCR not downmodu-
lated, but instead it was upregulated three times as much as
that on wild-type 2B4 cells (Figure 5A). These observations sug-
gest the possibility that mPY1-3 mutant may function as a dom-
inant-negative protein that interferes with additional pathways of
TCR downmodulation.
LAPTM5andCD3z Interact andColocalize in Lysosomes
Because lysosomal activity is required for LAPTM5-mediated
CD3z degradation (data not shown), we next investigated
whether these two proteins might interact in the lysosomal com-
partment. We stained spleen T cells before and after CD3 stim-
ulation with anti-CD3z, anti-LAPTM5, and anti-LAMP1 to identify
lysosomes. In unstimulated T cells, LAPTM5 was localized in ly-
sosomes and CD3z was at the perimembrane region (Figure 6A,
upper panels). However, after CD3 stimulation, a fraction of the
CD3z translocated to the lysosomes, where it colocalized with
LAPTM5 (Figure 6A, lower panels). To investigate whether
LAPTM5 and CD3z interact, we prepared lysates from 2B4 cells
expressing both LAPTM5 and CD3z by using a mild detergent,
digitonin, and immunoprecipitated LAPTM5. Immunoblot analy-
sis of the immunoprecipitates reproducibly detected the CD3z
chain (Figure 6B and Figure S7). Curiously, much less CD3z
was detected compared to the amount of LAPTM5. These
results demonstrate that LAPTM5 and CD3z interact in the lyso-
somal compartment in T cells.
DISCUSSION
We have identified a lysosomal protein that negatively regulates
surface TCR expression and T cell activation. LAPTM5 functions
to downmodulate cell-surface TCR expression on DP thymo-
cytes during T cell development and on peripheral T cells after
CD3 stimulation. Deficiency in LAPTM5 results in elevated prolif-
eration and cytokine production by T cells in response to CD3
stimulation in vitro, enhanced ex vivo responses, and prolonged
DTH responses in vivo. Conversely, enforced expression
of LAPTM5 results in reduced surface TCR amounts and
reduced cytokine production. These results illustrate a unique
Figure 4. LAPTM5 Downregulates Surface
TCR by Promoting the Degradation of
CD3z Chain
(A) Left panel: surface TCR expression in 2B4 cells
expressing GFP (orange line) or LAPTM5 (blue
line); right panel: the protein amounts of endoge-
nous CD3z and CD33 in 2B4 cells expressing
GFP or LAPTM5. (B) 2B4 cells expressing GFP or
LAPTM5 were stimulated for 1 day with plate-
bound anti-CD3 (left panel) or with PMA plus iono-
mycin (right panel), and the amount of IL-2 in the
culture supernatant was measured. (C) Normal
spleen T cells were transduced with retrovirus
expressing either LAPTM5-IRES-hCD8 or CD3z-
IRES-GFP and analyzed for surface TCR expres-
sion. Left panel: FACS profile of virus-transduced
spleen T cells; middle panel: surface TCR expres-
sion on gated cell population; right panel: average
± SD of three independent experiments. *, p < 0.05
when compared to untransduced cells or to cells
expressing both LAPTM5 and CD3z (unpaired
t test).38 Immunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc.
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T cell activation by a lysosomal protein.
Laptm5/ and wild-type spleen T cells expressed similar
amounts of cell-surface TCR in the resting state. After CD3 stim-
ulation, Laptm5/ T cells were able to downmodulate TCR, but
the amounts of surface TCR were consistently higher than that
found on wild-type T cells. Although the increase in the TCR ex-
pression on Laptm5/ T cells was modest, one has to take into
consideration the fact that the increased TCR expression was
observed while the T cells were undergoing continuous down-
modulation of surface TCR. Therefore, the cumulative physiolog-
ical effect of the slightly increased TCR expression could be
much greater and sufficient to cause T cell hyperactivation. It
is worth noting that these assays were performed in the absence
of pharmacologic agents such as protein-synthesis inhibitors.
This straightforward assay allowed us to demonstrate an abnor-
mality in TCR metabolism without any confounding artifacts,
such as might be introduced by blocking new protein synthesis
or excess manipulation of spleen T cells.
Several lines of evidence indicate that LAPTM5 regulates cell-
surface TCR expression through the selective degradation of
CD3z. First, anti-CD3-induced CD3z degradation was reduced
in Laptm5/ T cells, and this preceded and quantitatively corre-
lated with the kinetics of the increased surface TCR. Second,
LAPTM5 deficiency resulted in increased protein levels of
CD3z in DP thymocytes as well as elevated surface expression
of TCR. A similar phenotype has been observed in mice lacking
SLAP or c-Cbl (Sosinowski et al., 2001; Naramura et al., 1998),
although these mice had a greater increase in the expression
of these molecules than the Laptm5/ mice. The fact that
SLAP and c-Cbl are both involved in the degradation of CD3z
Figure 5. TCR Downmodulation Requires PY Motifs and the UIM of
LAPTM5
(A) Ability of wild-type and mutant LAPTM5 to downmodulate surface TCR in
2B4 cells. Data are presented as percentage of TCRb expression on GFP+
versus GFP cells. The results of three independent experiments (mean ±
SD) are shown. *, p < 0.001 as compared with GFP-transduced cells (unpaired
t test).
(B) Immunoblot analysis of wild-type andmutant LAPTM5 expression in sorted
GFP+ 2B4 cells transduced with each retrovirus.(Wang et al., 2001; Myers et al., 2005, 2006) is consistent with
a role for LAPTM5 in mediating CD3z degradation. Third,
enforced expression of LAPTM5 in 2B4 T cells resulted in de-
creased amounts of endogenous CD3z, reduced surface TCR
expression, and diminished cytokine production, and transduc-
tion of exogenous CD3z restored surface TCR expression and T
cell responses. Furthermore, enforced expression of LAPTM5 in
normal spleen T cells also induced TCR downmodulation, which
could be completely restored by coexpression of CD3z. This
complementation experiment strongly supports a CD3z-chain-
specific role for LAPTM5 in modulating cell-surface TCR expres-
sion. Fourth, LAPTM5 and CD3z interacted and colocalized in T
cells. We conclude from these studies that LAPTM5 regulates
cell-surface TCR expression and T cell activation by promoting
CD3z degradation. However, the possibility that LAPTM5 may
regulate T cell activation by targeting additional proteins cannot
be excluded at this point. Because LAPTM5 deficiency resulted
in only a partial inhibition of CD3z degradation, it is likely that
both LAPTM5-dependent and -independent pathways mediate
its degradation. The finding that overexpression of LAPTM5
alone caused a reduction of CD3z and a complete inhibition of
TCR signaling in 2B4 cells further implies that the LAPTM5
Figure 6. LAPTM5 and CD3z Colocalize in the Lysosome and Inter-
act Physically
(A) Localization of LAPTM5, LAMP1, and CD3z in normal spleen T cells before
() and after CD3 stimulation.
(B) Coprecipitation of LAPTM5 and CD3z. 2B4 cells expressing retrovirally
transduced LAPTM5 and CD3z were lysed with digitonin and subjected to im-
munoprecipitation with antibodies against LAPTM5 or control rabbit IgG. The
precipitates were resolved by SDS PAGE and blotted with antibodies against
CD3z (upper panel) or LAPTM5 (lower panel).Immunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc. 39
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capable of achieving sufficient inhibition of T cell activation.
Laptm5/ spleen T cells expressed higher amounts of sur-
face TCR, as well as CD3z proteins, than did wild-type T cells
only after CD3 stimulation, suggesting that LAPTM5 regulates
CD3z degradation in a ligand-dependent manner. Consistent
with this interpretation, LAPTM5 colocalized with CD3z in normal
spleen T cells only after CD3 stimulation. Furthermore, Laptm5/
DP thymocytes, which are undergoing positive and negative
selection and thereby are stimulated through their TCR, ex-
pressed higher amounts of surface TCR and cellular CD3z,
whereas Laptm5/ SP thymocytes, which have already under-
gone selection, expressed identical amounts of surface TCR and
CD3z as wild-type SP thymocytes. Direct TCR stimulation is
apparently no longer required in the 2B4 T hybridoma cell line
where overexpressed LAPTM5 was able to interact with CD3z
and mediate its degradation without the requirement for CD3
stimulation. However, our data in normal T cells and thymocytes
indicate that LAPTM5-mediated CD3z degradation is regulated
by TCR stimulation, presumably as a feedback mechanism to
prevent prolonged TCR signaling.
Deficiency in c-Cbl results in enhanced TCR signaling and
positive selection of thymocytes because of the elevated surface
TCR expression on DP thymocytes (Naramura et al., 1998). Par-
adoxically, peripheral T cells lacking c-Cbl respond rather poorly
to CD3 stimulation in terms of both proliferation and total tyrosine
phosphorylation. Because c-Cbl is expressed at a much lower
amount in mature T cells as compared to that in thymocytes
(Naramura et al., 1998), it is likely that the absence of c-Cbl
increases the TCR signaling on DP thymocytes and allows for
positive selection of thymocytes with lower TCR responsiveness
to become mature T cells. Laptm5/ DP thymocytes also
expressed increased TCR on DP thymocytes, but, in contrast
to c-Cbl deficiency, Laptm5/ mature T cells still exhibited en-
hanced responses to TCR stimulation. The similar phenotype in
thymocytes but opposite responses by mature T cells observed
in mice lacking LAPTM5 or c-Cbl could be attributable to the dif-
ferential expression patterns of these molecules. Laptm5 is ex-
pressed at higher amounts in the spleen than in the thymus
(Scott et al., 1996). Therefore, it is conceivable that the positively
selected Laptm5/ thymocytes can maintain their hyperres-
ponsiveness in the periphery relative to wild-type T cells, which
express higher amounts of LAPTM5. In this regard, it will be
interesting to inactivate Laptm5 specifically in thymocytes or pe-
ripheral T cells and investigate T cell function in vivo. Studies thus
far have revealed that multiple proteins, including SLAP, c-Cbl,
Cbl-b, and perhaps SLAP-2 (Holland et al., 2001; Pandey
et al., 2002; Loreto et al., 2002), are involved in the regulation
of surface TCR expression. SLAP and c-Cbl are predominantly
expressed and function in DP thymocytes, whereas Cbl-bmainly
functions in mature T cells. However, although c-Cbl and Cbl-b
predominantly function in thymocytes and mature T cells, re-
spectively, they appear to functionally compensate for each
other because Cbl-b and c-Cbl double deficiency exhibits
a much more severe defect both in mature T cells and in thymo-
cytes than seen inmice singly deficient for either gene (Naramura
et al., 2002; Huang et al., 2006). LAPTM5 functions both in the
thymus and in the periphery, presumably downstream of SLAP
and/or Cbl, and it promotes CD3z degradation. Therefore, TCR40 Immunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc.metabolism is regulated by multiple differentially expressed pro-
teins that have distinct as well as overlapping functions to allow
precise control of cell-surface TCR expression in response to the
different external signals encountered during T cell development
and activation.
It has recently been shown that SLAP functions as an adaptor
for the E3 ubiquitin ligase c-Cbl and that these two proteins
together mediate the ubiquitination and subsequent degradation
of CD3z (Myers et al., 2005, 2006). Interestingly, LAPTM5 con-
tains a UIM that overlaps with the second PY motif. We found
that LAPTM5-mediated TCR downmodulation in 2B4 cells re-
quired the UIM. It is tempting to speculate that LAPTM5 might
bind the ubiquitinated CD3z and promote its degradation in the
lysosomal compartment. Moreover, we found that the PY motifs
of LAPTM5 are critical for TCR downmodulation. Because PY
motifs are known to interact with WW domains involved in pro-
tein-protein interactions, it is conceivable that additional proteins
with WW domains might also be involved in CD3z degradation.
Recently, LAPTM5 was found to interact in 293T cells with
Nedd4, a HECT-type E3 ubiquitin ligase that plays multiple roles
in protein transport, through the PY motifs of LAPTM5 and the
WW domains of Nedd4 (Pak et al., 2006). In addition, LAPTM5
UIM was shown to bind ubiquitinated GGA3, an adaptor protein
involved in endosomal and lysosomal sorting. The interaction
of LAPTM5 with both Nedd4 and GGA3 appears to be essential
for its lysosomal localization (Pak et al., 2006). Moreover, in a
functional-proteomics mapping of a TGF-b signaling system,
LAPTM5 was shown to interact with Smurf2, a ubiquitin ligase
for Smads, and inhibit TGF-b signaling in HepG2 cells (Colland
et al., 2004). Although the physiological significance of LAPTM5
interactions with Nedd4, GGA3, and Smurf2 remains to be es-
tablished, these results suggest that LAPTM5 contains multiple
functional domains that control its localization and interaction
with other proteins. Intriguingly, we reproducibly detected
much lower amounts of CD3z than LAPTM5 when the LAPTM5
was immunoprecipitated. Because LAPTM5 interacts with multi-
ple proteins, it is possible that LAPTM5 antibodies pulled down
multiple proteins, with only a fraction being CD3z chain. Alterna-
tively, the small amount of CD3z detected in the LAPTM5 immu-
noprecipitates may be due to LAPTM5 overexpression in 2B4
cells.
Identification of LAPTM5 as a new regulator that mediates
CD3z degradation and inhibits T cell activation raises many
questions. How do LAPTM5 and other molecules involved in
TCR metabolism, including SLAP and Cbl family proteins, coo-
perate to regulate TCRmetabolism? Are there any human immu-
nodeficiencies or autoimmune diseases that are associated with
dysregulated LAPTM5 function? It is interesting to note that
Laptm5 gene is inactivated by either chromosomal deletion or
promoter methylation in four cases of human multiple myeloma
(Hayami et al., 2003), raising the possibility that LAPTM5 may
also have a tumor-suppressor function in humans.
EXPERIMENTAL PROCEDURES
Generation of Laptm5-Gene-Targeted Mice
A targeting vector was constructed to replace exon 1 and a part of the
promoter region with the neomycin gene. The C57BL/6-derived Bruce4
ESCs were transfected with the linearized targeting vector, and 2 days after
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GANC (only for the first two days). ESC colonies were expanded and subjected
to genomic PCR to identify homologous recombinants with the use of primers
flanking 50 and 30 homology regions and neo primers. The sequences are as
follows: 50 primer, s157459, 50-TGTGTCTATGTGTTCGTGTG-30; 30 primer,
as169968, 50-CGCATCAGTCTACCTAAACA-30; neos, 50-TCGCCTTCTAT
CGCCTTCTT-30; and neoas, 50-ATAGCCGAATAGCCTCTCCA-30. PCR was
performed at 95C for 2 min, followed by 30 cycles of amplification at 95C
for 10 s, 60C for 20 s, and 68C for 10 min with LA-Taq polymerase (TAKARA
Bio., Japan). Mouse genotypes were determined by PCR using primers
Laptm5s161549 (50-ATGGAGATGTGTGAGAAGCC-30), Laptm5as161994
(50-TGCCTGCTTCTCCCTACCAA-30), and neos at 95C for 2 min, followed by
30 cycles of amplification at 95C for 5 s, 60C for 10 s, and 72C for 1 min
with Taq polymerase (TOYOBO, Japan). Chimeric mice were bred with
C57BL/6 mice to obtain heterozygotes, which were then crossed to obtain
homozygotes. The Laptm5/ mice are in C57BL/6 background. Mice were
maintained in specific-pathogen-free conditions, and all experiments were
approved by the Animal Facility Committee of the RIKEN Yokohama Institute.
Antibodies and Other Reagents
Polyclonal rabbit antibodies were raised against a peptide (PPKTPEGDPAPP-
PYSEV) located near the C terminus of mouse LAPTM5. The specificity of the
LAPTM5 antibodieswas verified by both intracellular staining andwestern-blot
analysis of lysates derived of 293T cells transfected with a Laptm5 expression
vector. The following commercial antibodies were used in these studies: FITC-
anti-CD4 (RM4-5), PE-anti-CD8 (Ly-2), APC-anti-CD33 (2C11), PE-anti-TCRb
(H57-597), PE-B220 (RA3-6B2), FITC-anti-CD43, FITC-anti-IgM, PE-anti-
IgD, and APC-B220 for FACS staining (purchased from BD Biosciences);
anti-mouse CD3z (H146, CEDARLANE), anti-CD33 (M-20, Santa Cruz), anti-
human CD3z (6B10.2, Santa Cruz), anti-phosphotyrosine (4G10, Upstate),
anti-GFP (IE4, Stressgen), anti-Flag (M5, Sigma), anti-Actin (Sigma), anti-
CD3d (M-20, Santa Cruz), anti-CD3g (C-20, Santa Cruz), and anti-phospho
Lck (pY505, BD Biosciences) for immunoblot analyses. The following phospho
antibodies were purchased from Cell Signaling: phospho ZAP70 (Try319),
phospho LAT (Tyr171), phospho Erk, phospho JNK, and phospho p38MAP ki-
nase. For intracellular staining, anti-CD3z (H146, CEDARLANE), anti-LAMP1
(1D4B, BD Biosciences), FITC-anti-rabbit IgG (Santa Cruz), Alexa555-anti-
rat IgG (Molecular probes), Streptavidin-Alexa647 (Molecular probes), and
PE-anti-IFN-g (XMG1.2, BD Biosciences) were used. For CFSE assay,
CellTrace CFSE Cell Proliferation Kit (Molecular Probes) was used. For T cell
stimulation, anti-CD33 (2C11, NA/LE, BD Biosciences), anti-CD28 (37.51,
eBioscience), IL-2 (R&D), anti-hamster IgG (Cappel), PMA (Sigma), and iono-
mycin (Sigma) were used.
Purification of Spleen T Cells, Proliferation, Cytokine
Production, and Ca2+ Influx
Spleen T cells were isolated via negative sorting with the IMag T cell purifica-
tion kit (BD Biosciences). 2B4 is a T cell hybridoma and has been described
previously (D’Oro et al., 2002). Cells were cultured in RPMI 1640 medium sup-
plemented with 10% FCS, 53 105 M 2-mercaptoethanol, 2 mM L-glutamine,
and 100 U/ml of penicillin and streptomycin. For proliferation assay, cells were
cultured for 1 or 2 days and pulsed for the last 6 hr with 1 mCi/well of [3H]
thymidine. Thymidine uptake was analyzed as described previously (Masuda
et al., 2007). IL-2 and IFN-g production were measured by ELISA with a kit
(BD Biosciences). Ca2+ influx experiments were performed as previously de-
scribed (Hikida et al., 2003). In brief, purified spleen T cells were suspended
at 107 cells/ml and incubated with 1.2 mM of Indo 1-AM (Dojindo) at 37C for
45 min in the dark. After washing, the cells were resuspended at 106 cells/ml,
stimulated with anti-CD3 followed by anti-hamster IgG, and immediately
analyzed with a LSR flow cytometer (BD Biosciences).
TCR Internalization and Recycling
TCR internalization was analyzed as described previously (Naramura et al.,
2002). In brief, spleen cells were labeled with phycoerythrin (PE)-conjugated
hamster anti-mouse TCRb and crosslinked with goat antibodies against ham-
ster IgG at 4C. Cells were then cultured at 37C for various times to allow TCR
internalization. At each time point, noninternalized antibodies were removed
by washing cells twice in ice-cold acidic buffer (PBS containing 1% BSA,pH 3.0), followed by immediate neutralization in PBS containing 1% BSA
and 0.5% NaN3, pH 7.4. Both treated and untreated cells were then stained
with FITC-anti-CD4 or FITC-anti-CD8 and analyzed for PE fluorescence on
gated CD4+ andCD8+ cells by flow cytometry. The percentage of TCR internal-
ization was calculated as described previously (Naramura et al., 2002).
For analysis of the recycling of internalized TCR, spleen cells were labeled as
described above and cultured for 30 min to allow for TCR internalization. Cells
were then washed twice with cold acidic buffer, followed by immediate
neutralization to remove noninternalized antibodies, and cultured at 37C
again for various times to allow for the recycling of the internalized TCR. At
each time point, half of the cells were treated with cold acidic buffer followed
by neutralization, stained with FITC-anti-CD4 or anti-CD8, and analyzed for PE
fluorescence on gated CD4+ and CD8+ cells. The percentage of TCR recycling
was calculated as previously described (Myers et al., 2005). For both TCR
internalization and recycling, the acid stripping of cells did not induce massive
cell death (Figure S8).
Immunoblot Analysis
Cells were lysed directly in SDS sample buffer and sonicated for 2 min. The ly-
sate was resolved in a 5%–20% gradient gel and transferred to immobilon-P
membranes (MILLIPORE). After blocking with 5% nonfat milk, the membranes
were incubated with primary antibodies and then horseradish peroxidase
(HRP)-conjugated secondary antibodies and developed with an enhanced
chemiluminescence light (ECL) reagent.
Construction of Laptm5-IRES-GFP Vector and Retroviral Infection
A 1.1 kb Laptm5 cDNA fragment was cloned into pMX-IRES-GFP retroviral
vector (Nosaka et al., 1999). Various LAPTM5 constructs were prepared as de-
scribed recently (Pak et al., 2006) by site-directed mutagenesis with a kit (Invi-
trogen). These retroviral constructs were transfected into the PHOENIX pack-
aging cell line, and the virus supernatant was prepared as described previously
(Nosaka et al., 1999). Virus transduction of the 2B4 T cell hybridoma and nor-
mal spleen T cells was carried out in the presence of 10 mg/ml of DOTAP
reagent (Roche).
Immunofluorescence
Spleen T cells were first treated with 10 mMNH4Cl for 2 hr and then stimulated
with plate-bound anti-CD3 for 6 hr. Cells were then fixed and permeabilized
with the Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosci-
ences); stained with anti-LAPTM5, anti-LAMP1, and anti-CD3z (H146);
washed three times; and stained with biotinylated anti-Hamster IgG. After
they were washed three times, the cells were further stained with FITC-anti-
rabbit IgG to detect LAPTM5, Alexa 555-anti-rat IgG to detect LAMP1, and
avidin-Alexa 647 to detect CD3z. After they were washed three times, the cells
were attached to glass slides via a cytospin and fixed with ProLong Gold anti-
fade reagent containing DAPI. For intracellular staining of thymocytes, cells
were first stained with FITC-anti-CD4 and APC-anti-CD8, fixed and permeabi-
lized with the Cytofix/Cytoperm Fixation/Permeabilization Solution Kit, and
stained with anti-CD3z followed by PE-anti-hamster IgG.
Coimmunoprecipitation of LAPTM5 and CD3z
2B4 cells (23 107) were first cultured in the presence of the lysosome inhibitor
NH4Cl for 2 hr and then lysed on ice for 60 min in a buffer containing 1% dig-
itonin (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 2 mM EDTA) in the presence of
a protease inhibitor cocktail for mammalian cells (Sigma). The lysate was
centrifuged for 20 min at 20,000 3 g, and the supernatant was precleared
with 100 ml of protein G sepharose beads (Amersham) three times at 1 hr inter-
vals and immunoprecipitated with anti-LAPTM5 or control rabbit IgG-conju-
gated protein G beads at 4C for 3 hr. The beads were then washed ten times
with the lysis buffer and resuspended in SDS sample buffer. The samples were
boiled for 5 min and subjected to immunoblot analyses.
Assay for T Cell Activation In Vivo
For the ex vivo assay, mice were first immunized intradermally in both hind
footpads with 80 mg of KLH (Sigma) in complete Freund’s adjuvant (CFA,
Difco). Seven days after immunization, whole lymph node cells (2 3 105 cells)
were prepared from popliteal draining lymph nodes and cultured in the pres-
ence of different doses of KLH. For proliferation assay, cells were culturedImmunity 29, 33–43, July 18, 2008 ª2008 Elsevier Inc. 41
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production, cells were cultured for 2 days and supernatants were harvested.
IL-2 concentration was determined by ELISA (eBioscience). For the DTH as-
say, mice were sensitized with 1.25 mg/ml mBSA (Sigma) in CFA subcutane-
ously at the base of the tail. Seven days after sensitization, mice were chal-
lenged with 0.3 mg/ml of mBSA in a 20 ml volume into one footpad, and an
equal volume of PBS was injected into another footpad. Footpad swelling
was measured by a caliper. Footpad swelling was determined as follows:
(cm) = [footpad thickness of mBSA-injected footpad (cm)]  [footpad thick-
ness of PBS-injected footpad (cm)] as described (Nakae et al., 2002).
SUPPLEMENTAL DATA
Supplemental Data include eight figures and can be found with this article
online at http://www.immunity.com/cgi/content/full/29/1/33/DC1/.
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